SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC

Launched by CANCER INSTITUTE AND HOSPITAL, CHINESE ACADEMY OF MEDICAL SCIENCES · Jun 10, 2024

Keywords

ClinConnect Summary

This clinical trial is studying two types of radiation treatments for patients with small-cell lung cancer that has spread to the brain. Specifically, it compares a targeted approach called stereotactic radiosurgery (SRS) and a method that avoids the memory area of the brain (hippocampal-avoidance whole brain radiation therapy, or HA-WBRT). The goal is to find out which treatment works better for patients who have 10 or fewer brain metastases, which are cancer spots in the brain.

To be eligible for this trial, participants need to be adults aged 18 to 80 who have been diagnosed with small-cell lung cancer within the last five years. They should have no more than 10 brain metastases, and these spots must be a certain size and located away from critical areas of the brain. Participants can expect to undergo specific assessments and follow-up visits for at least six months after treatment. It's important for potential participants to discuss any other health conditions or medications with their doctor, as some factors could affect their eligibility.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Investigators should consider these factors when selecting patients for this trial. Investigators also should consider all other relevant factors (medical and non-medical), as well as the risks and benefits of the study therapy, when deciding if a patient is an appropriate candidate for this trial.
• • 1. Adult patients (18-80 years of age) with Eastern Cooperative Oncology Group performance status 0-2 or Karnofsky performance score ≥ 70, expected life time more than 6 months;
• • 2. Pathologically (histologically or cytologically) proven diagnosis of small cell lung cancer within 5 years of registration. If the original histologic proof of malignancy is greater than 5 years, then pathological (i.e., more recent) confirmation is required (e.g., from a systemic or brain metastasis). Patients with de novo or recurrent small cell lung cancer are permitted;
• • 3. No more than 10 metastatic brain lesions with ≤5 cm in largest diameter and ≤150 ml in treated volume, confirmed by a high-resolution (thickness ≤2mm) , 3-dimensional T1-weighted postgadolinium magnetic resonance imaging (MRI) brain scan within 2 weeks of study initiation. All brain metastases must be outside a 5-mm margin around either hippocampus or optic pathways.
• • 4. Not all metastatic brain lesions are recommended or suitable for surgical resection after multidisciplinary team discussion. If part of metastatic brain lesions are resected, the patient is permitted for enrollment evaluation at least two weeks after resection; 5 Patients must have the psychological ability and general health that permits completion of the study requirements, all assessment (HVLT-R, MoCA, EORTC QLQ-C30) and required follow up (at least 6 months);
• • 6. At least one measurable BM according to the Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) criteria; 7. Women of childbearing potential and men who are sexually active should be willing and able to use medically acceptable forms of contraception during treatment on this study and for up to 180 days after completion of all treatment to prevent pregnancy or fathering a child; 8. Written informed consent (must be available before enrolment in the trial).
• Exclusion Criteria:
• • 1. Clinical or radiologic evidence of new, untreated, and/or progressive brain metastases prior to registration;
• • 2. Previous radiotherapy of the brain;
• • 3. Patients can not tolerate immobilization or are with MRI contraindication (i.e., cardiac pacemaker, implanted defibrillator, certain cardiac valve replacements, certain metal implants);
• • 4. Radiographic evidence of hydrocephalus or other architectural distortion of the ventricular system, leptomeningeal metastases, increased intracranial pressure requiring immediate depression surgery.
• • 5. Patients who have not yet recovered from acute high-grade (≥Grade 3) toxicities of prior therapies according Common Terminology Criteria for Adverse EventsVersion5.0 (CTC 5.0);
• • 6. Presence of other serious illnesses such as acute myocardial infarction, severe arrhythmia, or psychiatric disorders within the past 6 months;
• • 7. Known carcinoma \< 5 years ago (excluding carcinoma in situ of the cervix, basal cell carcinoma, squamous cell carcinoma of the skin) requiring immediate treatment interfering with study therapy;
• • 8. Pregnant or lactating women;
• • 9. Participation in another clinical study or observation period of competing trials, respectively;